U.S. markets closed
  • S&P 500

    3,841.47
    -11.60 (-0.30%)
     
  • Dow 30

    30,996.98
    -179.03 (-0.57%)
     
  • Nasdaq

    13,543.06
    +12.15 (+0.09%)
     
  • Russell 2000

    2,168.76
    +27.34 (+1.28%)
     
  • Crude Oil

    51.98
    -1.15 (-2.16%)
     
  • Gold

    1,855.50
    -10.40 (-0.56%)
     
  • Silver

    25.57
    -0.29 (-1.12%)
     
  • EUR/USD

    1.2174
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.0910
    -0.0180 (-1.62%)
     
  • GBP/USD

    1.3684
    -0.0046 (-0.34%)
     
  • USD/JPY

    103.7700
    +0.2650 (+0.26%)
     
  • BTC-USD

    31,869.51
    -789.18 (-2.42%)
     
  • CMC Crypto 200

    651.44
    +41.45 (+6.79%)
     
  • FTSE 100

    6,695.07
    -20.35 (-0.30%)
     
  • Nikkei 225

    28,631.45
    -125.41 (-0.44%)
     

Intrahepatic Cholangiocarcinoma Industry to 2030 - Insights, Epidemiology, and Market Forecast - ResearchAndMarkets.com

·5 min read

The "Intrahepatic Cholangiocarcinoma (ICCA) - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the ICCA, historical and forecasted epidemiology as well as the ICCA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The ICCA market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM ICCA market size from 2017 to 2030. The Report also covers current ICCA treatment practice/algorithm, market drivers, market barriers, unmet medical needs, SWOT analysis to curate the best of the opportunities, and assesses the underlying potential of the market.

Very few nonsurgical treatment options are available for ICCA. The standard treatment includes surgery, radiation therapy, and chemotherapy. New clinical approaches are also being evaluated including liver transplant, targeted therapies, and immunotherapies.

Intrahepatic Cholangiocarcinoma (ICCA) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of ICCA, Gender-specific Incident Cases of ICCA, Age-specific Incident Cases of ICCA, Stage-specific Incident Cases of ICCA, and Biomarker-specific Incident Cases of ICCA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Key Findings

  • In 2017, a total of 10,177 patients were affected with ICCA in the 7MM.

  • The United States contributes the largest share with 3,639 incident cases in 2017, acquiring near about 35.76% of the totals 7MM share. On the other hand, EU5 and Japan will account for 37.40% and 26.84% population share, respectively, by 2017.

  • ICCA is slightly common in males as compared to females.

Intrahepatic Cholangiocarcinoma (ICCA) Market Outlook

Intrahepatic cholangiocarcinoma (ICCA) is the type of CCA that forms in the bile ducts inside the liver. The commonly available modalities for the treatment of ICCA include surgery and radiation therapies for curative intent and systemic therapies, including chemotherapy and chemoradiotherapy, for the surgery of ineligible patients.

Surgical resection is the mainstay for the treatment of ICCA. The main goal of the surgery is the hepatic resection with negative margins. Since this type of cancer occurs in the bile ducts inside the liver, surgery may include removing the section or wedge of the liver, and its extent depends on tumor size and location.

Locoregional therapies such as RFA, TACE, DEB-TACE or TACE drug-eluting microspheres, and TARE with yttrium-90 microspheres have shown to be effective in a retrospective analysis of patients with ICCA. Besides these, radiation therapy is also a locoregional treatment option for unresectable ICCA. Fewer patients with ICCA are also given ablation. Although all guidelines recommend radiofrequency ablation (RFA) as a standard treatment for patients with small, early-stage HCC not suitable for surgical therapies, in some cases, patients with ICCA are also treated with RFA.

Since the chances of recurrence are higher in these cancers, the mortality rate becomes higher. The high rates of local and distant recurrence following surgery justify the consideration of adjuvant treatment. As per the NCCN guidelines, the adjuvant treatment for indication include adjuvant capecitabine, gemcitabine monotherapy or combined with cisplatin or capecitabine, capecitabine monotherapy or combined with cisplatin or oxaliplatin, and 5-fluorouracil monotherapy or combined with cisplatin or oxaliplatin.

Additionally, treatment options for advanced BTCs include enrollment in the clinical trial, systemic therapies (gemcitabine or fluoropyrimidine-based chemotherapy, or pembrolizumab for patients with MSI-H/dMMR tumors), fluoropyrimidine-based chemoradiation, and radiotherapy without additional chemotherapy.

Key Findings

  • The market size of Intrahepatic Cholangiocarcinoma (ICCA) in the 7MM was USD 99.78 million in 2017.

  • Currently, the market size for early stage ICCA majorly includes surgery with adjuvant chemotherapy and chemoradiation therapy. For the advanced and metastatic stage, systemic chemotherapy is the only option. There is no established second-line systemic therapy following progression after first-line treatment although chemotherapeutic agents either in monotherapy or in combination are used.

  • To meet the increasing demand for the treatment of ICCA, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, and NTRK1, NTRK2 or NTRK3, may increase the market size in the coming years, assisted by an increase in the incident population of ICCA and awareness of the disease.

  • The overall dynamics of ICCA market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Pemazyre (Pemigatinib), Rozlytrek (Entrectinib), Melphalan/HDS, Ivosidenib (AG-120), Infigratinib, Futibatinib (TAS-120), Bintrafusp alfa, Derazantinib, Larotrectinib, E7090, Copanlisib (BAY 80-6946), and Regorafenib.

  • Among the upcoming therapies, Futibatinib (TAS-120) is expected to take the highest market share. It is expected to generate the market size of USD 6.56 million in the launch year, 2024.

  • Out of these emerging therapies, therapies with biomarkers IDH1/IDH2 mutations and FGFR translocations are found to be most promising.

  • Among the 7MM, the United States accounts for the highest market size of ICCA in comparison with EU5 and Japan.

Companies Mentioned

  • Incyte Corporation

  • Roche

  • Delcath Systems

  • Basilea Pharmaceutica

  • Agios Pharmaceuticals

  • Loxo Oncology/Bayer

  • Qed Therapeutics

  • Janssen Pharmaceutical

  • Taiho Oncology

  • Redhill Biopharma

  • Glaxosmithkline

  • Merck/Glaxosmithkline

  • Eisai

  • Taiho Pharmaceutical/Servier

  • Bayer

  • Sorrento Therapeutics/Yuhan Corporation

  • Hutchison Medipharma

  • Jiangsu Hengrui Medicine

  • Astrazeneca

  • Eli Lilly

  • Servier Laboratories

  • Genoscience Pharma

  • Forma Therapeutics

  • Array Biopharma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jdm0f2

View source version on businesswire.com: https://www.businesswire.com/news/home/20201204005317/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900